Semaglutide: Key Differences and Synergies The comparison of Cagrilintide vs semaglutide highlights how dual-pathway modulation may offer more robust results than single-agent approaches alone
BPC-157: The Tissue Protector Body Protection Compound-157 is derived from a naturally occurring protein found in gastric juice
Where to Inject It BPC-157 is most commonly used as a subcutaneous or intramuscular injection
Major Criteria Congenital multiple contractures, characteristically adduction-flexion contractures and/or talipes equinovarus (clubfoot) Characteristic craniofacial features, which are evident at birth or in early infancy Characteristic cutaneous features including skin hyperextensibility, easy bruisability, skin fragility with atrophic scars, increased palmar wrinkling Minor Criteria Recurrent/chronic dislocations Pectus deformities (flat, excavated) Spinal deformities (scoliosis, kyphoscoliosis) Peculiar fingers (tapering, slender, cylindrical) Progressive talipes deformities (valgus, planus, cavum) Large subcutaneous hematomas Chronic constipation Colonic diverticula Pneumothorax/ pneumohemothorax Nephrolithiasis/cystolithiasis Hydronephrosis Cryptorchidism in males Strabismus Refractive errors (myopia, astigmatism) Glaucoma/elevated intraocular pressure Myopathic EDS (mEDS) If a person meets the diagnostic criteria for mEDS, genetic testing should be done to confirm the diagnosis
